<DOC>
	<DOCNO>NCT01871727</DOCNO>
	<brief_summary>The purpose trial ass efficacy safety E7777 ( improve purity ONTAK ) patient persistent recurrent cutaneous T-cell lymphoma . A lead-in dose-finding part use determine dose E7777 use test efficacy safety .</brief_summary>
	<brief_title>A Trial E7777 Persistent Recurrent Cutaneous T-Cell Lymphoma</brief_title>
	<detailed_description>This multicenter , open-label , single-arm study E7777 participant recurrent persistent Cutaneous T-Cell Lymphoma ( CTCL ) . The study consist initial lead-in phase ( dose E7777 select ) , follow Main Study . Participants move three phase study : Pretreatment Phase , Treatment Phase , Extension Phase Follow-up Period .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>Participants must meet follow criterion include study : 1 . Age great equal 18 year . 2 . Histopathologic diagnosis CTCL ( mycosis fungoides [ MF ] Sezary Syndrome [ SS ] ) , confirm skin biopsy , lymph node , blood assessment , current disease . 3 . CD25 assaypositive tumor , define detectable CD25 great equal 20 % total lymphoid infiltrate biopsied skin lesion immunohistochemistry . 4 . CTCL disease stage study entry follow , accord ISCL/EORTC ( Olsen 2011 ) . LeadIn Phase : Stage IA IV , except participant CNS involvement . Main Study : Stage IA IVA1 ( exclude IVA2 IVB ) , follow : However , N0 N1 allow ; Excludes know CTCL involvement bone marrow 5 . History prior therapy CTCL follow : must prior therapy , number prior therapy allow . Topical treatment ( except topical chemotherapy ) steroid consider prior therapy . 6 . A minimum washout period 4 week previous CTCL therapy recommend first dose E7777 . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 LeadIn Phase performance status 0 1 Main Study . 8 . Life expectancy great equal 3 month LeadIn Phase great equal 12 month Main Study . 9 . Adequate bone marrow reserve evidence : platelet great equal 100,000/mm3 ( 100 x 10^9/L ) clinically stable hemoglobin great equal 9 g/dL ( 90 g/L ) hematocrit great equal 27 % without transfusion support 10 . Normal hepatic function evidence : bilirubin alkaline phosphatase less equal 1 x upper limit normal ( ULN ) . aspartate aminotransferase ( AST ) less equal 75 U/L alanine aminotransferase ( ALT ) less equal 100 U/L . albumin great equal 3.0 g/dL ( 30 g/L ) . 11 . Adequate renal function evidence serum creatinine less equal 1.8 mg/dL ( 158 umol/L ) OR calculate creatinine clearance great equal 50 mL/min ( per CockcroftGault formula ) less 2+ protein OR 24 hour urine creatinine clearance great equal 50 mL/minute 24 hour urine protein less 1g . 12 . Provide write informed consent prior studyspecific screening procedure . Exclusion Criteria Participants meet follow criterion exclude study : 1 . CTCL disease CNS involvement 2 . Prior denileukin diftitox therapy 3 . Use topical steroid within 14 day Day 1 initial therapy allow , 4 . Prior malignancy CTCL within past 5 year ( except nonmelanoma skin cancer carcinoma situ cervix ) 5 . Major surgery within 2 week study enrollment 6 . Significant uncontrolled infection require specific antiinfective therapy 7 . Females pregnant ( positive urine test ) breastfeed 8 . Any history medical condition concomitant medical condition , opinion investigator , would compromise participant 's ability safely complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Persistent Recurrent Cutaneous T-Cell Lymphoma</keyword>
	<keyword>E7777</keyword>
</DOC>